Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Malvern Discussion of Analytical Toolkit for Biopharmaceutical Applications is Now Available Online

Published: Friday, April 12, 2013
Last Updated: Friday, April 12, 2013
Bookmark and Share
View online at http://bit.ly/MALOTACB.

A recent Malvern Instruments sponsored webinar, presented by specialists from the company, examined the need for specific analytical tools for biopharmaceutical applications.

The recording of the live event, which attracted more than 600 registrants, is now available to view online at http://bit.ly/MALOTACB.

In the presentation, Mark Pothecary and Paul Clarke, Product Manager and Product Group Manager respectively for Nanoparticle and Molecular Characterization at Malvern Instruments, discuss a variety of the analytical technologies that are available for the growing biopharmaceutical industry.

They provide fresh insights into the use of a number of well-established characterization techniques, including light scattering and size exclusion chromatography (GPC/SEC) and illustrate the use of these techniques in combination, showing how they can provide a wide range of complementary information useful to protein scientists.

The continued shift within the industry towards biopharmaceuticals has resulted in the need for analytical instrumentation that can quickly deliver compelling solutions to meet rapidly evolving analytical and regulatory challenges.

In particular the move towards drugs using biomolecules as the active has stimulated advances in new analytical procedures. As well as traditional techniques, such as GPC/SEC and dynamic light scattering (DLS), which can be performed separately or in combination (SEC-DLS), new technologies including microrheology and resonant mass measurement are rapidly becoming essential components of the analytical toolkit.

Within Malvern Instruments, the company’s global Bioscience Development Initiative recognizes the unprecedented pace of development in biopharmaceuticals and the onus this places on analytical instrumentation companies to quickly deliver solutions to a host of rapidly evolving analytical and regulatory challenges.

Malvern’s Bioscience Development Initiative is focused specifically on the requirements of the biopharmaceutical sector, most notably the biochemical and biophysical characterization needs relating to formulation and product development.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Malvern takes ACHEMA Visitors from R&D Through to Product QC
Visitors to the Malvern Instruments stand at ACHEMA 2012 will see how the company’s range of complementary materials characterization technologies and instrumentation support the needs of manufacturing industry.
Wednesday, March 28, 2012
Malvern Scientists will lead Protein Characterization Workshop at PEGS Summit
Drs Kevin Mattison, Ulf Nobbmann and Jason Sanchez will lead a workshop at the 7th Annual PEGS.
Tuesday, September 13, 2011
Scientific News
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!